Phase 2 Brenipatide (LY3537031) Trial for IBS-D, Apr 2026
ClinicalTrials.gov Studies
Summary
NIH's ClinicalTrials.gov has registered a new Phase 2 clinical trial (NCT07545759) evaluating subcutaneously administered brenipatide (LY3537031) against placebo in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study will assess tolerability, safety, and efficacy over approximately 35 weeks. No regulatory approval, efficacy finding, or compliance obligation is established by this registry entry.
“The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D).”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 686 changes logged to date.
What changed
This ClinicalTrials.gov registry entry records a new Phase 2 clinical trial (NCT07545759) for brenipatide (LY3537031) in IBS-D. The entry documents the trial's purpose, intervention type, and approximate 35-week duration but does not constitute a regulatory approval, efficacy determination, or compliance requirement.
Pharmaceutical companies and clinical investigators conducting IBS-D drug development programs may use this registry entry to track competitor pipeline activity. Trial sponsors subject to FDAAA 801 clinical trial registration requirements should ensure their own registrations remain current and include required results data upon completion.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Phase 2 NCT07545759 Kind: PHASE2 Apr 22, 2026
Abstract
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.
The study will last approximately 35 weeks.
Conditions: Irritable Bowel Syndrome, Diarrhea
Interventions: LY3537031, Placebo
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.